Index S&P 500
P/E 44.69
EPS (ttm) 4.65
Insider Own 0.39%
Shs Outstand 83.90M
Perf Week 3.99%
Market Cap 17.49B
Forward P/E 12.93
EPS next Y 16.08
Insider Trans -14.56%
Shs Float 83.77M
Perf Month -2.72%
Income 418.00M
PEG 5.35
EPS next Q 3.48
Inst Own 98.43%
Short Float 2.30%
Perf Quarter -6.90%
Sales 12.90B
P/S 1.36
EPS this Y 9.43%
Inst Trans -2.81%
Short Ratio 2.58
Perf Half Y 5.06%
Book/sh 93.86
P/B 2.22
EPS next Y 8.34%
ROA 2.08%
Short Interest 1.92M
Perf Year 4.10%
Cash/sh 6.38
P/C 32.58
EPS next 5Y 8.36%
ROE 4.27%
52W Range 179.58 - 234.09
Perf YTD -8.51%
Dividend Est. 2.23 (1.07%)
P/FCF 20.01
EPS past 5Y -11.14%
ROI 3.30%
52W High -11.17%
Beta 1.02
Dividend TTM 2.88 (1.39%)
Quick Ratio 1.02
Sales past 5Y 2.87%
Gross Margin 25.22%
52W Low 15.79%
ATR (14) 3.53
Dividend Ex-Date May 28, 2024
Current Ratio 1.17
EPS Y/Y TTM -66.36%
Oper. Margin 8.80%
RSI (14) 48.78
Volatility 1.72% 1.57%
Employees 67000
Debt/Eq 0.76
Sales Y/Y TTM -13.28%
Profit Margin 3.24%
Recom 1.85
Target Price 245.69
Option/Short Yes / Yes
LT Debt/Eq 0.61
EPS Q/Q -330.17%
Payout 60.36%
Rel Volume 1.06
Prev Close 207.97
Sales Surprise 0.51%
EPS Surprise 1.32%
Sales Q/Q -17.44%
Earnings Apr 25 BMO
Avg Volume 747.28K
Price 207.94
SMA20 -0.23%
SMA50 -2.49%
SMA200 -2.47%
Trades
Volume 793,521
Change -0.01%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-25-24 Upgrade
Argus
Hold → Buy
$250
Feb-26-24 Initiated
Leerink Partners
Outperform
$260
Feb-09-24 Initiated
Evercore ISI
In-line
$240
Jan-03-24 Initiated
Barclays
Equal Weight
$222
Sep-06-23 Initiated
HSBC Securities
Hold
$210
Dec-12-22 Downgrade
Citigroup
Buy → Neutral
$275 → $250
Sep-19-22 Downgrade
Argus
Buy → Hold
Aug-22-22 Resumed
Morgan Stanley
Overweight
$300
Jan-28-22 Downgrade
Deutsche Bank
Buy → Hold
$330 → $294
Jan-11-21 Upgrade
Argus
Hold → Buy
$245
Jan-11-21 Downgrade
Wolfe Research
Peer Perform → Underperform
Jan-08-21 Downgrade
Wolfe Research
Outperform → Peer Perform
Jul-14-20 Upgrade
BofA Securities
Neutral → Buy
$194 → $220
Jul-13-20 Upgrade
Wolfe Research
Peer Perform → Outperform
Jun-02-20 Resumed
Deutsche Bank
Buy
$210
May-15-20 Upgrade
Mizuho
Neutral → Buy
$158 → $186
Apr-29-20 Downgrade
KeyBanc Capital Markets
Overweight → Sector Weight
Apr-27-20 Upgrade
Wolfe Research
Underperform → Peer Perform
Apr-27-20 Upgrade
Citigroup
Neutral → Buy
$204 → $214
Jan-08-20 Initiated
Wells Fargo
Overweight
$210
Show Previous Ratings
Apr-24-24 10:25PM
10:23PM
09:27PM
09:19PM
Apr-22-24 09:16AM
05:34AM
Loading…
Apr-19-24 05:34AM
Apr-18-24 12:10PM
10:01AM
Apr-16-24 08:42AM
Apr-15-24 07:00AM
Apr-12-24 09:10AM
Apr-11-24 06:59AM
Apr-10-24 06:49AM
Apr-09-24 09:03AM
Apr-08-24 09:34AM
07:09AM
Loading…
07:09AM
07:03AM
07:00AM
Apr-05-24 07:00AM
Apr-03-24 11:01AM
11:00AM
Apr-02-24 11:20AM
07:00AM
Apr-01-24 12:42PM
08:00AM
Mar-30-24 01:30AM
Mar-29-24 09:00AM
Mar-28-24 11:08PM
08:00AM
Mar-27-24 07:00AM
07:03AM
Loading…
Mar-25-24 07:03AM
Mar-20-24 07:00AM
Mar-18-24 09:44AM
Mar-16-24 10:29AM
Mar-15-24 09:25AM
Mar-11-24 11:00AM
Mar-08-24 10:26AM
Mar-07-24 07:00AM
Mar-05-24 07:00AM
Feb-27-24 12:08AM
Feb-26-24 08:45AM
05:01AM
Feb-21-24 12:00PM
08:19AM
Feb-19-24 06:28AM
Feb-16-24 09:41AM
07:15AM
12:59AM
(Thomson Reuters StreetEvents)
Feb-15-24 03:29PM
12:48PM
09:30AM
08:10AM
07:37AM
07:35AM
07:30AM
(Associated Press Finance)
06:56AM
Feb-12-24 09:16AM
Feb-08-24 10:00AM
04:08AM
Feb-07-24 09:05AM
Feb-05-24 08:16AM
Feb-01-24 04:55PM
07:00AM
Jan-31-24 07:00AM
Jan-16-24 06:58AM
Jan-12-24 06:57AM
Jan-11-24 11:21AM
Jan-10-24 08:02AM
Jan-05-24 04:45AM
Jan-02-24 07:00AM
Dec-29-23 09:23AM
Dec-26-23 03:59PM
Dec-21-23 09:03AM
Dec-17-23 05:05AM
Nov-30-23 07:46PM
Nov-27-23 08:35AM
Nov-24-23 07:21AM
Nov-22-23 05:04AM
Nov-20-23 07:00AM
Nov-16-23 07:00AM
Nov-08-23 07:00AM
Nov-06-23 05:07AM
Oct-31-23 01:17AM
Oct-28-23 02:29PM
Oct-27-23 08:30AM
08:30AM
Oct-26-23 11:13PM
(Thomson Reuters StreetEvents)
04:19PM
02:51PM
(American City Business Journals)
10:36AM
09:30AM
08:48AM
08:15AM
08:08AM
07:06AM
(Associated Press Finance)
06:58AM
Oct-23-23 06:26AM
Oct-19-23 10:01AM
Oct-16-23 08:30PM
(The Wall Street Journal)
Oct-13-23 08:28AM
Laboratory Corp. of America Holdings operates as a life sciences company, which engages in the provision of vital information to help health professionals make clear and confident decisions. It operates through the Drug Development and Diagnostics segments. The Drug Development segment consists of lead optimization, preclinical safety assessment, analytical services, clinical trials, central laboratories, biomarkers, and companion diagnostics, market access, and technology solutions. The Diagnostics segment includes primary care, women's health, specialty medicine, oncology, ACOs, and hospitals and health systems. The company was founded in 1971 and is headquartered in Burlington, NC.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Schroeder Mark S EVP, Pres Diagnostics & COO Apr 01 '24 Sale 217.29 6,477 1,407,387 5,036 Apr 03 08:35 AM Summy Amy B. EVP, Chief Marketing Officer Apr 01 '24 Sale 217.29 3,500 760,515 3,975 Apr 03 08:34 AM van der Vaart Sandra D EVP, Chief Legal Officer Mar 28 '24 Sale 216.74 3,553 770,077 7,637 Mar 29 05:54 PM Schroeder Mark S EVP, Pres Diagnostics & COO Mar 07 '24 Option Exercise 117.09 2,119 248,114 10,084 Mar 11 08:59 AM Schroeder Mark S EVP, Pres Diagnostics & COO Mar 07 '24 Sale 218.45 5,048 1,102,736 5,036 Mar 11 08:59 AM Summy Amy B. EVP, Chief Marketing Officer Mar 07 '24 Sale 218.45 227 49,588 3,859 Mar 11 08:56 AM EISENBERG GLENN A Chief Financial Officer, EVP Feb 21 '24 Option Exercise 163.63 14,054 2,299,656 58,099 Feb 22 03:05 PM EISENBERG GLENN A Chief Financial Officer, EVP Feb 21 '24 Sale 215.97 34,504 7,451,866 23,595 Feb 22 03:05 PM DiVincenzo Jonathan P. EVP, Pres, Central Labs & Intl Feb 21 '24 Sale 215.49 500 107,745 3,401 Feb 22 03:04 PM van der Vaart Sandra D EVP, Chief Legal Officer Feb 13 '24 Sale 226.45 237 53,669 7,637 Feb 15 08:32 AM van der Vaart Sandra D EVP, Chief Legal Officer Feb 08 '24 Sale 222.06 259 57,514 7,637 Feb 09 12:19 PM van der Vaart Sandra D EVP, Chief Legal Officer Feb 05 '24 Sale 220.57 193 42,570 7,637 Feb 06 03:47 PM Wilkinson Peter J SVP, Chief Accounting Officer Nov 16 '23 Sale 210.71 1,384 291,627 2,087 Nov 20 12:23 PM ANDERSON KERRII B Director Aug 08 '23 Sale 211.57 5,000 1,057,832 15,275 Aug 10 08:55 AM van der Vaart Sandra D EVP, Chief Legal Officer Jun 29 '23 Sale 240.00 212 50,880 7,605 Jul 03 11:52 AM Kirchgraber Paul R CEO, Covance Drug Development May 19 '23 Option Exercise 182.51 4,300 784,793 17,246 May 23 08:06 AM Kirchgraber Paul R CEO, Covance Drug Development May 19 '23 Sale 216.91 4,300 932,707 12,946 May 23 08:06 AM Schroeder Mark S EVP, Pres Diagnostics & COO May 18 '23 Option Exercise 130.60 1,500 195,900 8,187 May 22 03:08 PM Schroeder Mark S EVP, Pres Diagnostics & COO May 18 '23 Sale 216.77 1,500 325,155 6,687 May 22 03:08 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite